Medtronic (MDT) stock jumps after beating Q4 revenue expectations, driven by strong growth in cardiovascular and diabetes tech.

Medtronic (MDT) to report Q4 2026 results on 6/3, expected revenue of $9.61B & EPS of $1.55. Recent acquisition of SPR Therapeutics adds to neuromodulation business. Analyst…

Medtronic to report Q4 2026 results with expected revenue of $9.61B and EPS of $1.55. Dividend yield is 3.83%.